<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25867" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Newborn Screening</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dubay</surname>
            <given-names>Kelly S.</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zach</surname>
            <given-names>Terence L.</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kelly Dubay declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Terence Zach declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25867.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">Newborn screening is a state-run healthcare initiative that encompasses the process of parental education, infant screening, appropriate follow-up, diagnostic testing, disease management, and continued evaluation.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;The newborn screen itself is a specific set of laboratory evaluations and point-of-care&#x000a0;examinations performed on newborn infants in an attempt to identify clinically occult but potentially serious disorders that require expedient intervention.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;Nearly four million infants&#x000a0;undergo screening annually<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>, with approximately 3,400 infants each year receiving early intervention for diseases identified by uniform newborn screening.<xref ref-type="bibr" rid="article-25867.r2">[2]</xref>&#x000a0;</p>
        <p>The disorders targeted by newborn screening are generally those that, without intervention, would cause significant morbidity, mortality, or intellectual disability.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;However, the disorders selected for screening have been and continue to be influenced by technological capacity, efficiency and cost-effectiveness of screening, the potential for therapeutic intervention, and other political and ethical considerations.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref><xref ref-type="bibr" rid="article-25867.r3">[3]</xref>&#x000a0;The newborn screening program in the United States encompasses three main branches: hearing loss, critical cardiac heart defects, and a collection of metabolic, hematologic, endocrine, and other inheritable disorders.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref><xref ref-type="bibr" rid="article-25867.r4">[4]</xref><xref ref-type="bibr" rid="article-25867.r3">[3]</xref><xref ref-type="bibr" rid="article-25867.r5">[5]</xref></p>
        <p>
<bold>Program Structure</bold>
</p>
        <p>Newborn screening in the United States is organized on a state-by-state basis with guidance from the Recommended Uniform Screening Panel (RUSP).<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;This RUSP consists of 35 core diseases and 26 secondary diseases, which are those that can be detected in the differential diagnosis of a core disorder.<xref ref-type="bibr" rid="article-25867.r5">[5]</xref>&#x000a0;The RUSP is updated by Health &#x00026; Human Services with input from the Advisory Committee on Heritable Disorders in Newborns and Children.<xref ref-type="bibr" rid="article-25867.r5">[5]</xref>&#x000a0;This committee was formed by the Congressional &#x0201c;Newborn Screening Saves Lives Act&#x0201d; that was passed in 2007 and reauthorized in 2019.<xref ref-type="bibr" rid="article-25867.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>Brief History</bold>
</p>
        <p>Newborn screening was first envisioned in the 1960s with the disease phenylketonuria, which achieved nearly universal screening in the United States by the 1970s.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;Newborn screening programs then experienced an incredible expansion in the early 2000s when the advent of tandem mass spectroscopy provided the capacity to&#x000a0;rapidly and easily screen for more diseases.<xref ref-type="bibr" rid="article-25867.r6">[6]</xref>&#x000a0;Programs to screen for newborn hearing loss began in the 1980s,<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;with current U.S. Preventive Services Task Force grade B recommendation.<xref ref-type="bibr" rid="article-25867.r7">[7]</xref>&#x000a0;Screening for congenital heart disease was added to the&#x000a0;Recommended Uniform Screening Panel in 2011.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Blood Sample</bold>
</p>
        <p>The largest component of newborn screening involves obtaining a blood sample to screen for metabolic, hematologic, endocrine, and other inheritable disorders. A sample of the infant&#x02019;s blood is obtained ideally within 24-48 hours of birth, though premature or ill infants may require alterations to this screening timeline.<xref ref-type="bibr" rid="article-25867.r4">[4]</xref>&#x000a0;The infant&#x02019;s heel is pricked, and&#x000a0;several drops of blood are placed on a filter paper card that is then sent for processing.<xref ref-type="bibr" rid="article-25867.r5">[5]</xref>&#x000a0;Laboratory analysis methods include electrophoresis, enzyme measurement, immunoassays, tandem mass spectroscopy, and polymerase chain reaction.<xref ref-type="bibr" rid="article-25867.r4">[4]</xref><xref ref-type="bibr" rid="article-25867.r5">[5]</xref>&#x000a0;One important mathematical distinction is that a screen results in a risk value, as opposed to a diagnostic test that reports a value in comparison to a reference range.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;If the screen produces a positive result, then, depending on the particular protocol for that disease, either a repeat screen or a disease-specific confirmatory test should be conducted as soon as possible.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;Results are typically directed to the infant&#x02019;s primary care provider, though some states have dedicated follow-up centers.<xref ref-type="bibr" rid="article-25867.r4">[4]</xref></p>
        <p>
<bold>Hearing Screen&#x000a0;</bold>
</p>
        <p>An infant&#x02019;s hearing may be screened by two different non-invasive methods; otoacoustic emissions (OAE) or auditory brainstem response (ABR).<xref ref-type="bibr" rid="article-25867.r4">[4]</xref><xref ref-type="bibr" rid="article-25867.r8">[8]</xref><xref ref-type="bibr" rid="article-25867.r9">[9]</xref>&#x000a0;The OAE further subdivides into transient evoked (TEOAE) or distortion product (DPOAE), of which the TEOAEs are the more common measurement.<xref ref-type="bibr" rid="article-25867.r10">[10]</xref>&#x000a0;The ABR is further subdivided into (standard) ABR and automated auditory brainstem response (AABR), of which AABR is more common during screening.<xref ref-type="bibr" rid="article-25867.r10">[10]</xref>&#x000a0;During the OAE screen, the infant is fitted with a probe placed snugly in the ear canal; this device emits a sound and then records the response from cochlear hair cell movements.<xref ref-type="bibr" rid="article-25867.r8">[8]</xref><xref ref-type="bibr" rid="article-25867.r9">[9]</xref>&#x000a0;During the AARB screen, the infant is fitted with a scalp electrode that records the electroencephalographic waves resulting from external auditory stimulation.<xref ref-type="bibr" rid="article-25867.r8">[8]</xref>&#x000a0;Both methods of testing produce either a &#x0201c;pass&#x0201d; or &#x0201c;fail&#x0201d; result. Every facility has its own algorithm for testing, though it is common to utilize the AABR if the infant initially fails the OAE.<xref ref-type="bibr" rid="article-25867.r10">[10]</xref>&#x000a0;If an infant does not pass hearing screening while in the newborn nursery, then the infant&#x02019;s caregivers follow up with their primary care provider for repeat screening and, if necessary, more advanced evaluation with otolaryngological and audiological consultations.<xref ref-type="bibr" rid="article-25867.r8">[8]</xref>&#x000a0;The goal is to perform screening by one month, obtain a diagnostic evaluation by three months, and begin intervention by six months.<xref ref-type="bibr" rid="article-25867.r11">[11]</xref><xref ref-type="bibr" rid="article-25867.r7">[7]</xref>&#x000a0;</p>
        <p>
<bold>Pulse Oximetry&#x000a0;</bold>
</p>
        <p>An infant is screened for critical congenital heart defects with peripheral pulse oximetry, which&#x000a0;uses light to calculate the percentage of hemoglobin that is bound to oxygen.<xref ref-type="bibr" rid="article-25867.r12">[12]</xref>&#x000a0;Two main premises exist for pulse oximetry as a screen for congenital heart defects: 1) hypoxemia, the most common early sign of a cyanotic congenital heart defect, presents before cyanosis may be evident, and 2) a patent ductus arteriosus may provide life-sustaining mixing of oxygenated and deoxygenated blood, depending on the defect, that results in a difference between pre-ductal (right upper extremity) and post-ductal (either lower extremity) oxygen saturations.<xref ref-type="bibr" rid="article-25867.r12">[12]</xref><xref ref-type="bibr" rid="article-25867.r13">[13]</xref>&#x000a0;If the pulse oximetry screen is concerning for a congenital heart defect, a diagnostic echocardiogram should be promptly obtained.<xref ref-type="bibr" rid="article-25867.r12">[12]</xref><xref ref-type="bibr" rid="article-25867.r14">[14]</xref>&#x000a0;The care team should conduct a thorough physical exam, initiate appropriate interventions, and refer the infant to cardiology for further workup and management.<xref ref-type="bibr" rid="article-25867.r14">[14]</xref>&#x000a0;</p>
        <p>Below is a list of the critical congenital heart defects that are the target of pulse oximetry screening.<xref ref-type="bibr" rid="article-25867.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary atresia</p>
          </list-item>
          <list-item>
            <p>Tricuspid atresia</p>
          </list-item>
          <list-item>
            <p>Truncus arteriosus</p>
          </list-item>
          <list-item>
            <p>Total anomalous pulmonary venous return</p>
          </list-item>
          <list-item>
            <p>Hypoplastic left heart syndrome</p>
          </list-item>
          <list-item>
            <p>D-Transposition of the great vessels&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Double outlet right ventricle</p>
          </list-item>
          <list-item>
            <p>Ebstein anomaly</p>
          </list-item>
          <list-item>
            <p>Interrupted aortic arch</p>
          </list-item>
          <list-item>
            <p>Single ventricle complex</p>
          </list-item>
          <list-item>
            <p>Coarctation of the aorta</p>
          </list-item>
          <list-item>
            <p>Tetralogy of Fallot&#x000a0;</p>
          </list-item>
        </list>
        <p>Below is a list of the diseases and disorders included on the&#x000a0;Recommended Uniform Screening Panel (RUSP) as of July 2018.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic
<list list-type="bullet"><list-item><p>Organic acid condition</p></list-item><list-item><p>Propionic acidemia</p></list-item><list-item><p>Methylmalonic acidemia</p></list-item><list-item><p>Isovaleric acidemia</p></list-item><list-item><p>3-Methylcrotonyl-CoA carboxylase deficiency</p></list-item><list-item><p>3-Hydroxy-3-methylglutaric aciduria</p></list-item><list-item><p>Holocarboxylase synthase deficiency</p></list-item><list-item><p>Beta-ketothiolase deficiency</p></list-item><list-item><p>Glutaric acidemia type 1</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Fatty acid oxidation disorder
<list list-type="bullet"><list-item><p>Carnitine uptake or transport defect</p></list-item><list-item><p>Medium-chain acyl-CoA dehydrogenase deficiency</p></list-item><list-item><p>Very long-chain acyl-CoA dehydrogenase deficiency</p></list-item><list-item><p>Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency</p></list-item><list-item><p>Trifunctional protein deficiency</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Amino acid disorders
<list list-type="bullet"><list-item><p>Argininosuccinic aciduria</p></list-item><list-item><p>Citrullinemia type 1</p></list-item><list-item><p>Maple syrup urine disease</p></list-item><list-item><p>Homocystinuria</p></list-item><list-item><p>Classic phenylketonuria</p></list-item><list-item><p>Tyrosinemia type 1</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Endocrine disorders
<list list-type="bullet"><list-item><p>Primary congenital hypothyroidism</p></list-item><list-item><p>Congenital adrenal hyperplasia</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Hemoglobin disorders
<list list-type="bullet"><list-item><p>Sickle cell anemia (SS disease)</p></list-item><list-item><p>Beta thalassemia (S beta)</p></list-item><list-item><p>SC disease (SC)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Other
<list list-type="bullet"><list-item><p>Biotinidase deficiency</p></list-item><list-item><p>Critical congenital heart disease</p></list-item><list-item><p>Cystic fibrosis</p></list-item><list-item><p>Classic galactosemia</p></list-item><list-item><p>Glycogen storage disease type II (Pompe)</p></list-item><list-item><p>Hearing loss</p></list-item><list-item><p>Severe combined immunodeficiencies</p></list-item><list-item><p>Mucopolysaccharidosis type 1</p></list-item><list-item><p>X-linked adrenoleukodystrophy</p></list-item><list-item><p>Spinal muscular atrophy due to homozygous deletion of exon 7 in SMN1</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25867.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>General Screening Criteria</bold>
</p>
        <p>A screen must meet certain established criteria before it can be implemented for mass screening. The original&#x000a0;guidelines were articulated by the World Health Organization based on the Wilson and Jungner 1968 publication, which has been expanded in follow-up discussions to incorporate the implications of genomic testing.<xref ref-type="bibr" rid="article-25867.r15">[15]</xref>&#x000a0;A screening program should have a predetermined objective, an identified need, a specific target population, and evidence of efficacy.<xref ref-type="bibr" rid="article-25867.r15">[15]</xref>&#x000a0;The screening program should have in place strategies for quality assurance, routine evaluation, and methods to reduce the risk.<xref ref-type="bibr" rid="article-25867.r15">[15]</xref>&#x000a0;The population should have equitable access to screening, autonomy in participation, and a guarantee of confidentiality.<xref ref-type="bibr" rid="article-25867.r15">[15]</xref>&#x000a0;Finally, the test itself should have high sensitivity (low &#x0201c;miss&#x0201d; rate), be acceptable to patients, and produce rapid results.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref><xref ref-type="bibr" rid="article-25867.r15">[15]</xref></p>
        <p>
<bold>Medical Ethics</bold>
</p>
        <p>The U.S. newborn screening program attempts to uphold the core pillars of medical ethics: beneficence, non-maleficence, justice, and autonomy. The benefit of newborn screening is clear: early identification of affected infants provides an opportunity to initiate life-saving or life-altering treatment.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref><xref ref-type="bibr" rid="article-25867.r4">[4]</xref>&#x000a0;The individual harms of newborn screening&#x000a0;are minimal (heel prick) but, in the case of a false-positive, may initiate unnecessary follow-up diagnostic evaluations that are painful to the infant, stressful for the family, and expensive for the healthcare system.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;Newborn screening programs uphold the principle of justice by&#x000a0;striving to ensure that all newborns have access to this screening program.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;Participation in newborn screening is automatic and, in most states, mandatory; this loss of autonomy is deemed justifiable given the potential for significant benefit with negligible individual harm.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref><xref ref-type="bibr" rid="article-25867.r4">[4]</xref></p>
        <p>
<bold>Resource Allocation</bold>
</p>
        <p>As in all healthcare paradigms, the scarcity of resources forces a strategic plan in utilization. The cost of this mass screening program must be considered against its potential benefits. Factors to consider include the following: prevalence of the disease, cost of testing materials and equipment, the expense of follow-up investigations, the impact of early intervention, and funding for continued research. One example of this cost-benefit balancing act is in the selection of screening cut-off values; designing a less sensitive screen would result in fewer false-positives but at the risk of missing a true disease.</p>
        <p>
<bold>Technological Advancement</bold>
</p>
        <p>As technology continues to push the boundaries of the information providers can easily and inexpensively obtain, healthcare teams must meet these advancements with conscientious consideration for the ethical implications.<xref ref-type="bibr" rid="article-25867.r15">[15]</xref>&#x000a0;Identifying variants of uncertain clinical significance could&#x000a0;burden families with years of stress and extensive workups. Determining&#x000a0;carrier status may undermine that patient&#x02019;s privacy when making future decisions about reproduction. Diagnosing disorders that become symptomatic in adulthood may add unnecessary stress yet may allow earlier intervention.<xref ref-type="bibr" rid="article-25867.r1">[1]</xref><xref ref-type="bibr" rid="article-25867.r3">[3]</xref><xref ref-type="bibr" rid="article-25867.r15">[15]</xref></p>
        <p>
<bold>Neonatal Intensive Care Unit</bold>
</p>
        <p>Infants in the neonatal intensive care unit (NICU) require additional considerations regarding newborn screening. Premature newborns have immature enzymes and metabolic instability, which result in more false-positive results.<xref ref-type="bibr" rid="article-25867.r6">[6]</xref>&#x000a0;To ensure appropriate sensitivity, infants in the NICU should be re-screened seven days after admission if they were initially screened younger than 24 hours of age.<xref ref-type="bibr" rid="article-25867.r6">[6]</xref>&#x000a0;Infants receiving total parenteral nutrition are frequently falsely identified as having carnitine deficiency.&#x000a0;This false-positive is due to the lack of L-carnitine in the&#x000a0;total parenteral nutrition substrate, and the infant's levels will likely normalize with the introduction of normal feeding.<xref ref-type="bibr" rid="article-25867.r6">[6]</xref>&#x000a0;Most of the diseases on the newborn screening panel manifest after weeks or months after birth; however, some disorders become symptomatic before the results of the&#x000a0;newborn screening are known.<xref ref-type="bibr" rid="article-25867.r6">[6]</xref><xref ref-type="bibr" rid="article-25867.r1">[1]</xref>&#x000a0;Infants with symptoms suspicious for inborn errors of metabolism should be evaluated for acidemia, hypoglycemia, and hyperammonemia.<xref ref-type="bibr" rid="article-25867.r6">[6]</xref>&#x000a0;If an infant in the NICU has not had an echocardiogram, pulse oximetry screening should be performed prior to discharge.<xref ref-type="bibr" rid="article-25867.r6">[6]</xref>&#x000a0;Many aspects of prematurity and the NICU experience can predispose to hearing loss, including hypoxia, hyperbilirubinemia, antibiotics, ambient noise, and prolonged supplemental oxygen.<xref ref-type="bibr" rid="article-25867.r9">[9]</xref><xref ref-type="bibr" rid="article-25867.r6">[6]</xref>&#x000a0;All infants residing in the NICU for more than five days should have their hearing screened with&#x000a0;automated auditory brainstem response to&#x000a0;screen for neural hearing loss.<xref ref-type="bibr" rid="article-25867.r11">[11]</xref><xref ref-type="bibr" rid="article-25867.r9">[9]</xref></p>
      </sec>
      <sec id="article-25867.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>General Disorders</bold>
</p>
        <p>The disorders of the newborn screening panel each have their own prevalence, and each respective screen has its own sensitivity, specificity, and rates of false positives or negatives. These evaluations are for screening purposes only; should a provider encounter an ill infant, the differential diagnosis may need to be expanded to include disorders that were initially&#x000a0;reported as negative on the newborn screen.<xref ref-type="bibr" rid="article-25867.r4">[4]</xref>&#x000a0;Another clinical consideration is the state-by-state variation of diseases included on the newborn screen. Not only is each state responsible for choosing the diseases to be included in newborn screening, but they also select the method of laboratory analysis as well as the cut-off values.<xref ref-type="bibr" rid="article-25867.r4">[4]</xref>&#x000a0;Each provider should be aware of the contents of the&#x000a0;newborn screening panel for the state of their practice.</p>
        <p>
<bold>Hearing Loss</bold>
</p>
        <p>The prevalence of hearing loss&#x000a0;is about 0.1% in full-term births and 3% or greater in preterm births.<xref ref-type="bibr" rid="article-25867.r8">[8]</xref>&#x000a0;One clinical concern is&#x000a0;that as many as half of the infants who fail the newborn hearing screening are lost to follow-up.<xref ref-type="bibr" rid="article-25867.r9">[9]</xref>&#x000a0;Healthcare teams should&#x000a0;employ patient-retainment strategies, such as communicating the need for additional testing,&#x000a0;verifying&#x000a0;current contact information, reducing barriers such as transportation and costs,&#x000a0;normalizing hearing interventions, and emphasizing the availability and value of early support.<xref ref-type="bibr" rid="article-25867.r9">[9]</xref><xref ref-type="bibr" rid="article-25867.r16">[16]</xref><xref ref-type="bibr" rid="article-25867.r11">[11]</xref>&#x000a0;</p>
        <p>One common reason an infant fails a hearing screen is an obstruction of the external auditory canal by amniotic fluid.<xref ref-type="bibr" rid="article-25867.r9">[9]</xref>&#x000a0;Failed hearing screens should be repeated after a few hours to allow amniotic fluid to clear the canal.<xref ref-type="bibr" rid="article-25867.r9">[9]</xref>&#x000a0;When evaluating possible hearing loss, providers should be aware of the type of screen used. The otoacoustic emissions&#x000a0;method screens&#x000a0;the auditory pathway only up to the cochlear hair cells, whereas the&#x000a0;auditory brainstem response method&#x000a0;evaluates the complete auditory and neural pathways.<xref ref-type="bibr" rid="article-25867.r8">[8]</xref><xref ref-type="bibr" rid="article-25867.r9">[9]</xref>&#x000a0;Though hearing screening has a high sensitivity of 92%,<xref ref-type="bibr" rid="article-25867.r7">[7]</xref>&#x000a0;providers should not hesitate to rescreen children, especially after illnesses associated with hearing loss.<xref ref-type="bibr" rid="article-25867.r9">[9]</xref>&#x000a0;For example, the most common non-inherited form of hearing loss is due to prenatal cytomegalovirus infection, which may involve progressive hearing loss after the newborn period.<xref ref-type="bibr" rid="article-25867.r9">[9]</xref>&#x000a0;Hearing loss may be a component of a syndrome in about 15% of cases, which indicates the necessity to not only identify hearing loss but to also pursue a thorough evaluation of all systems to a diagnostic conclusion.<xref ref-type="bibr" rid="article-25867.r9">[9]</xref><xref ref-type="bibr" rid="article-25867.r8">[8]</xref></p>
        <p>
<bold>Congenital Heart Defects</bold>
</p>
        <p>Congenital heart defects (CHD) occur in approximately 0.4% to 1% of live births, with up to one-quarter of those categorized as &#x0201c;critical&#x0201d; (CCHD), defined as ductal-dependent heart lesions that require invasive treatment within the first month of life.<xref ref-type="bibr" rid="article-25867.r12">[12]</xref>&#x000a0;To put these numbers in perspective: CHDs are the most common congenital malformation, and CCHDs are the leading cause of death in infancy.<xref ref-type="bibr" rid="article-25867.r12">[12]</xref>&#x000a0;Screening for a congenital heart defect begins in pregnancy with the standard fetal anatomic survey; if an abnormality is suspected, then the patient is referred for a detailed fetal echocardiogram.<xref ref-type="bibr" rid="article-25867.r12">[12]</xref>&#x000a0;Despite these prenatal screenings, approximately 50% of CCHDs may be missed, and nearly 30% of infants born with a CCHD are discharged without a diagnosis.<xref ref-type="bibr" rid="article-25867.r12">[12]</xref>&#x000a0;Given these statistics, it is vital that providers understand the process and limitations of pulse oximetry screening for CCHD. An exact diagnosis of the type of defect is not necessary, but the healthcare team must&#x000a0;be able to recognize the need for cardiac testing, initiate stabilization, and seek appropriate consultation.<xref ref-type="bibr" rid="article-25867.r13">[13]</xref>&#x000a0;After immediate stabilization of the cardiovascular system, providers should investigate other conditions, such as chromosomal abnormalities, that commonly present alongside congenital heart defects.<xref ref-type="bibr" rid="article-25867.r13">[13]</xref>&#x000a0;</p>
        <p>Providers caring for infants and even children should bear in mind that a normal pulse oximetry screen in the newborn nursery does not definitively rule out critical cardiac heart defects.<xref ref-type="bibr" rid="article-25867.r14">[14]</xref>&#x000a0;The pulse oximetry screening test has a sensitivity of about 75% for CCHD in general;<xref ref-type="bibr" rid="article-25867.r17">[17]</xref>&#x000a0;however, the most commonly missed CCHD is coarctation of the aorta, for which the pulse oximetry screen has a sensitivity of only 36%.<xref ref-type="bibr" rid="article-25867.r18">[18]</xref>&#x000a0;Although the pulse oximetry screening has a very high specificity of 99.9%, clinicians should be sure to consider other sources of hypoxemia in the infant, such as sepsis or inborn errors of metabolism.<xref ref-type="bibr" rid="article-25867.r18">[18]</xref><xref ref-type="bibr" rid="article-25867.r13">[13]</xref>&#x000a0;The false-positive rate (0.14%) of pulse oximetry screening can be effectively decreased by waiting to screen at least 24 hours after birth.<xref ref-type="bibr" rid="article-25867.r17">[17]</xref>&#x000a0;</p>
        <p>
<bold>Summary</bold>
</p>
        <p>In summary, newborn screening is a far-reaching public health initiative that has reduced infant mortality and morbidity. Through simple point-of-care&#x000a0;procedures and a single-prick blood collection, the newborn screen can aid in the detection of hearing loss, critical cardiac heart defects, and numerous metabolic, hematologic, endocrine, and genetic disorders. A provider should never be deterred from pursuing a&#x000a0;diagnostic evaluation simply because the screening was negative, as no screen is perfect, and symptoms may evolve over time. Likewise, providers should follow best-practice guidelines to reduce false-positives and the subsequent burden of diagnostic follow-up. Premature infants and those requiring stays in the NICU have unique considerations; providers should consult their team and healthcare organization to determine optimal screening. Communication remains a significant opportunity for improvement; healthcare teams should strive to effectively explain the goals and limitations of these screens to expecting and new caregivers. As research and technology continue to make enormous strides in diagnostic and management strategies, healthcare professionals should remain engaged in the ongoing conversation about the&#x000a0;ethical considerations of mass screening.&#x000a0;</p>
      </sec>
      <sec id="article-25867.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Newborn screening confers substantial benefits. Early detection of hearing loss has an estimated lifetime economic savings of greater than $400,000 per patient identified.<xref ref-type="bibr" rid="article-25867.r16">[16]</xref>[Level 5]&#x000a0;More importantly, timely intervention&#x000a0;mitigates&#x000a0;the developmental delay that may result from the detection of hearing loss in late childhood versus early infancy.<xref ref-type="bibr" rid="article-25867.r19">[19]</xref>[Level&#x000a0;3] Pulse oximetry is a very specific, fairly sensitive, easy-to-perform, and cost-effective screening method to aid in the detection of critical congenital heart defects.<xref ref-type="bibr" rid="article-25867.r12">[12]</xref>[Level&#x000a0;4] Without screening, nearly half of infants with a&#x000a0;critical congenital heart defect would be discharged from the hospital without the intervention that could prevent significant morbidity and mortality.<xref ref-type="bibr" rid="article-25867.r12">[12]</xref>&#x000a0;Nearly four million infants&#x000a0;undergo screening annually<xref ref-type="bibr" rid="article-25867.r1">[1]</xref>,&#x000a0;with approximately 3,400 infants each year receiving early intervention for diseases identified by uniform newborn screening.<xref ref-type="bibr" rid="article-25867.r2">[2]</xref>&#x000a0;</p>
        <p>Newborn screening is an enormous healthcare initiative that requires the dedicated effort of&#x000a0;the entire healthcare team. The&#x000a0;principle opportunities for improvement involve screening&#x000a0;procedures, family education, infant follow-through, and future directions.&#x000a0;</p>
        <p>
<bold>Screening Procedures&#x000a0;</bold>
</p>
        <p>A screening program of this magnitude&#x000a0;requires significant administrative support. The equipment must be maintained, with the audiology equipment calibrated yearly.<xref ref-type="bibr" rid="article-25867.r8">[8]</xref>&#x000a0;The adequate protocol must be in place for efficient processing and transport of bloodwork to the appropriate facility. Most importantly, members of the healthcare team&#x000a0;should maintain up-to-date knowledge of&#x000a0;screening algorithms, including limitations and special considerations.<xref ref-type="bibr" rid="article-25867.r18">[18]</xref>&#x000a0;</p>
        <p>
<bold>Family Education</bold>
</p>
        <p>The obstetric team may play an increasing role in patient education regarding the process and value of newborn screening. Obstetricians should ensure that each mother has selected a pediatrician early in her second trimester for a seamless postpartum transition of care. Intake and triage staff should&#x000a0;verify the current&#x000a0;patient contact information. Nurses on the labor and delivery, as well as postpartum units, have perhaps the greatest opportunity to explain to the infant&#x02019;s&#x000a0;caregivers the role of newborn screening and the importance of close follow-up.<xref ref-type="bibr" rid="article-25867.r4">[4]</xref>&#x000a0;</p>
        <p>
<bold>Infant Follow-through</bold>
</p>
        <p>Pediatricians and family physicians, when encountering positive newborn screening results, will need to promptly order follow-up tests and offer general counseling to the infant&#x02019;s family. Providers should have a low threshold for referring families to geneticists and other specialists for more advanced counseling, whether concerning the infant&#x02019;s prognosis or the parents&#x02019; future reproductive decisions.&#x000a0;</p>
        <p>
<bold>Future Directions</bold>
</p>
        <p>Biomedical research is needed to expand the capacity and improve the precision of screening. A pharmaceutical investigation is required to offer effective intervention. As diagnostic and therapeutic technologies advance, specialists are needed to advocate for the inclusion of diseases into the recommended uniform screening panel. Furthermore,&#x000a0;representation in government is needed to ensure appropriate screening legislation and adequate funding allocation. As always, the healthcare field should remain engaged in discussions of the ethical implications of newborn screening.<xref ref-type="bibr" rid="article-25867.r15">[15]</xref></p>
      </sec>
      <sec id="article-25867.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25867&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25867">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25867/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25867">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25867.s6">
        <fig id="article-25867.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Newborn hearing screen by automated auditory brainstem response Contributed by Liannadavis / CC BY-SA (https://creativecommons.org/licenses/by-sa/4.0) 
https://upload.wikimedia.org/wikipedia/commons/3/37/NeonatalHearingScreening.jpg</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NeonatalHearingScreening" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25867.s7">
        <fig id="article-25867.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Newborn screening with blood obtained from heel prick Contributed from U.S. Air Force photo/Staff Sgt Eric T. Sheler / Public domain 
Page URL: https://commons.wikimedia.org/wiki/File:Phenylketonuria_testing.jpg</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Newborn__screening__heel__prick" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25867.s8">
        <fig id="article-25867.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Newborn hearing screen by otoacoustic emissions Contributed by U.S. Air Force photo/Samuel King Jr., 
( https://www.eglin.af.mil/News/Article-Display/Article/391747/medical-group-recognized-for-newborn-hearing-procedures/ )</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Newborn__hearing__screen__OAE" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25867.s9">
        <title>References</title>
        <ref id="article-25867.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCandless</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Mandatory newborn screening in the United States: History, current status, and existential challenges.</article-title>
            <source>Birth Defects Res</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>112</volume>
            <issue>4</issue>
            <fpage>350</fpage>
            <page-range>350-366</page-range>
            <pub-id pub-id-type="pmid">32115905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>Ten great public health achievements--United States, 2001-2010.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2011</year>
            <month>May</month>
            <day>20</day>
            <volume>60</volume>
            <issue>19</issue>
            <fpage>619</fpage>
            <page-range>619-23</page-range>
            <pub-id pub-id-type="pmid">21597455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailey</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>The Future of Newborn Screening: Why and How Partnerships Will Be Needed for Success.</article-title>
            <source>N C Med J</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-31</page-range>
            <pub-id pub-id-type="pmid">30622201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabie</surname>
                <given-names>NAV</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>The Current State of Newborn Screening in the United States.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>369</fpage>
            <page-range>369-386</page-range>
            <pub-id pub-id-type="pmid">30819343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Hattab</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Almannai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Newborn Screening: History, Current Status, and Future Directions.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>389</fpage>
            <page-range>389-405</page-range>
            <pub-id pub-id-type="pmid">29502920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kronn</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Navigating Newborn Screening in the NICU: A User's Guide.</article-title>
            <source>Neoreviews</source>
            <year>2019</year>
            <month>May</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>e280</fpage>
            <page-range>e280-e291</page-range>
            <pub-id pub-id-type="pmid">31261080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>US Preventive Services Task Force</collab>
            <article-title>Universal screening for hearing loss in newborns: US Preventive Services Task Force recommendation statement.</article-title>
            <source>Pediatrics</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>122</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-8</page-range>
            <pub-id pub-id-type="pmid">18595997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bentley</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Hearing Loss in Pediatrics: What the Medical Home Needs to Know.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>425</fpage>
            <page-range>425-436</page-range>
            <pub-id pub-id-type="pmid">30819346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wroblewska-Seniuk</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Dabrowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Szyfter</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mazela</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Universal newborn hearing screening: methods and results, obstacles, and benefits.</article-title>
            <source>Pediatr Res</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>415</fpage>
            <page-range>415-422</page-range>
            <pub-id pub-id-type="pmid">27861465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khoza-Shangase</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moroe</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Newborn hearing screening protocols and their outcomes: A systematic review.</article-title>
            <source>Int J Pediatr Otorhinolaryngol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>115</volume>
            <fpage>104</fpage>
            <page-range>104-109</page-range>
            <pub-id pub-id-type="pmid">30368368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <collab>American Academy of Pediatrics, Joint Committee on Infant Hearing</collab>
            <article-title>Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs.</article-title>
            <source>Pediatrics</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>4</issue>
            <fpage>898</fpage>
            <page-range>898-921</page-range>
            <pub-id pub-id-type="pmid">17908777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plana</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Zamora</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Suresh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fernandez-Pineda</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thangaratinam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ewer</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Pulse oximetry screening for critical congenital heart defects.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD011912</fpage>
            <pub-id pub-id-type="pmid">29494750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fillipps</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bucciarelli</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Cardiac evaluation of the newborn.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>471</fpage>
            <page-range>471-89</page-range>
            <pub-id pub-id-type="pmid">25836709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sholler</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Pulse oximetry screening of newborns: Not only a screening test for congenital heart disease.</article-title>
            <source>J Paediatr Child Health</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>168</fpage>
            <page-range>168-9</page-range>
            <pub-id pub-id-type="pmid">25047065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andermann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blancquaert</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Beauchamp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D&#x000e9;ry</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years.</article-title>
            <source>Bull World Health Organ</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>86</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-9</page-range>
            <pub-id pub-id-type="pmid">18438522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fort</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Newborn Hearing Screening: Making a Difference.</article-title>
            <source>N C Med J</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>96</fpage>
            <page-range>96-100</page-range>
            <pub-id pub-id-type="pmid">28420769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thangaratinam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zamora</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Ewer</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Pulse oximetry screening for critical congenital heart defects in asymptomatic newborn babies: a systematic review and meta-analysis.</article-title>
            <source>Lancet</source>
            <year>2012</year>
            <month>Jun</month>
            <day>30</day>
            <volume>379</volume>
            <issue>9835</issue>
            <fpage>2459</fpage>
            <page-range>2459-2464</page-range>
            <pub-id pub-id-type="pmid">22554860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oster</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kochilas</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Screening for Critical Congenital Heart Disease.</article-title>
            <source>Clin Perinatol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-80</page-range>
            <pub-id pub-id-type="pmid">26876122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25867.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomblin</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ambrose</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Oleson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Moeller</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Language Outcomes in Young Children with Mild to Severe Hearing Loss.</article-title>
            <source>Ear Hear</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>36 Suppl 1</volume>
            <issue>0 1</issue>
            <fpage>76S</fpage>
            <page-range>76S-91S</page-range>
            <pub-id pub-id-type="pmid">26731161</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
